Published in Clin Chem on June 01, 2004
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res (2010) 1.46
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res (2014) 1.19
Endocrine disruptors, environmental oxygen, epigenetics and pregnancy. Front Biosci (Elite Ed) (2011) 1.07
Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev (2009) 0.85
Genome-wide methylation profiling demonstrates hypermethylation in maternal leukocyte DNA in preeclamptic compared to normotensive pregnancies. Hypertens Pregnancy (2013) 0.81
Normal early pregnancy: a transient state of epigenetic change favoring hypomethylation. Epigenetics (2012) 0.81
Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk. J Cancer (2015) 0.80
Up-regulated expression and aberrant DNA methylation of LEP and SH3PXD2A in pre-eclampsia. PLoS One (2013) 0.79
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011) 2.91
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J Invest Dermatol (2003) 1.93
Circulating tumor cells in metastatic breast cancer--toward individualized treatment? N Engl J Med (2004) 1.89
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) 1.71
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol (2010) 1.60
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med (2012) 1.53
Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012) 1.51
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res (2004) 1.45
Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol (2004) 1.45
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer (2008) 1.44
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study. Transfusion (2005) 1.42
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol (2003) 1.31
A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012) 1.26
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood (2006) 1.18
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol (2010) 1.18
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci Rep (2013) 1.12
Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci U S A (2011) 1.11
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain (2005) 1.09
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res (2008) 1.08
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Conservative management of abnormally invasive placenta: four case reports. Acta Obstet Gynecol Scand (2013) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06